DOT1L and leukemia: EPZ-5676, a DOT1L KMT inhibitor, had anti-proliferative effects on both P31/FUJ and MLL translocation-induced leukemia cell lines similar to those reported in previous studies in other disease models (Fig. 5a, b)37,38.